04.02.2013 - European company and research leaders have urged EU heads to greenlight €80bn for Horizon2020.
The joint letter of the European Round Table of Industrialists (ERT) and European Research Council (ERC) arrived some days before the EU Council will decide over the proposed €80m R&D budget of the EU innovation programme from 2014-2020. „We call on Europe’s leaders to approve the €80bn funding programme for research and innovation, Horizon 2020. This will lay the foundations for growth in Europe“, said ERC chief Helga Nowotny and ERT head Leif Johansson. The stakeholders warned that „any reduction in the funding to support excellent research will result in Europe having limited means to attract outstanding talent in a highly competitive global market.“
The EU heads will meet this week after negotiations of the EU Summit last November failed. A week before Council President Hermann van Rompuy’s initial budget proposal was withdrawn, 44 Nobel laureates had already warned in about the consequences of budget cuts to research and innovation. Over 100,000 Internet users supported their call not to slash the European Research Council (ERC) budget for excellent fundamental research. However, initial ideas discussed by the heads of EU Member States at the end of November foresaw cutting the €80bn innovation programme’s proposed budget by 12% (about €10bn) or more in favour of agriculture and structural funds.
This time, the research lobbyists try to make a stronger case: “Industry has long realised that one of its most precious assets is people“, stressed Nowotny and Johansson. „A continued supply of well-trained scientists and entrepreneurs is essential, especially for SMEs and start-up companies. Europe’s future can only be built on its brains.“
04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.
03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.
29.04.2016 Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest in early-stage cancer treatments. The money raised by the fund, nearly half of which comes from investors in Asia, is the largest amount ever raised for such a cancer investment fund.
27.04.2016 More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).
21.04.2016 An expert panel’s final report on the fatal drug trial earlier this year in France states that the death of one of the participants was most likely caused by the drug’s toxicity and not by any violation of the rules.
21.04.2016 For up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The pre-clinical immuno-oncology candidate targets a protein believed to contribute to immunosuppressive effects of T-cells.
19.04.2016 British drug developer Heptares Therapeutics and mAb maker Kymab Ltd have partnered up in yet another immuno-oncology collaboration. The companies plan to discover antibody meds targeting a superfamily of receptors.
15.04.2016 Not every company is put off by the current stock market climate. Swiss biopharma company GeNeuro has gone public at Euronext Paris, raising €33m in the process. Others, meanwhile, have to find different ways to raise money.
13.04.2016 Despite political disturbances, 2015 was a good year for the biotech scene in Switzerland. Net sales increased by 5.1% to CHF5,133m and 400 additional people found jobs in the sector. As usual, the new numbers were presented at the annual Swiss Biotech Day – which set new records as well.